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Spasticity and muscle weakness is common in children with cerebral palsy (CP).
Spasticity can be treated with botulinum neurotoxin-A (BoNT-A), but this drug has also
been reported to induce muscle weakness. Our purpose was to describe the effect
on muscle strength in the lower extremities after BoNT-A injections in children with CP.
A secondary aim was to relate the effect of BoNT-A to gait pattern and range of motion.
Twenty children with spastic CP were included in the study, 8 girls and 12 boys (mean
age 7.7 years). All were able to walk without support, but with increased muscle tone
interfering with motor function and gait pattern. Sixteen children had unilateral spastic
CP and four bilateral spastic CP. Twenty-four legs received injections with BoNT-A in
the plantar flexor muscles. The children were tested before treatment, around 6 weeks
after at the peak effect of BoNT-A, and at 6 months after treatment, with measurement
of muscle strength, gait analysis, and range of motion. There were no differences in
muscle strength in plantar flexors of treated legs at peak effect compared to baseline.
Six months after treatment, there was still no change in untreated plantar flexor muscles,
but an increasing trend in plantar flexor strength in legs treated with BoNT-A. Parents
reported positive effects in all children, graded as: small in three children, moderate in
eight, and large in nine children. The gait analysis showed a small improvement in knee
extension at initial contact, and there was a small increase in passive range of motion
for ankle dorsiflexion. Two children had a period with transient weakness and pain.
We found that voluntary force production in plantar flexor muscles did not decrease
after BoNT-A, instead there was a trend to increased muscle strength at follow-up. The
increase may be explained as an effect of the blocking of involuntary nerve impulses,
leading to an opportunity to using and training the muscles with voluntary control.
Adequate muscle strength is important for maintaining the ability to walk and knowledge
of how a treatment affects muscle strength is useful when selecting interventions.
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INTRODUCTION
Spasticity is a common problem in children with cerebral palsy (CP) (SCPE, 2002; Himmelmann
et al., 2007), which may have an adverse effect on motor development (Gormley, 2001). About 80%
of CP is classified as spastic. Spasticity can be defined as a velocity-dependent increase in resistance
to passive movement (Sanger et al., 2003), which may prevent voluntary movement and cause
muscle shortening (contracture), which in turn can also affect skeletal development.
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It has been possible since the 1990s to treat spasticity with
botulinum neurotoxin A (BoNT-A). BoNT-A is injected directly
into the muscle and inhibits the release of neurotransmitter
at the neuromuscular junction, thus blocking nerve impulses
to the muscle (Simpson et al., 2008). The effect will increase
gradually over a few weeks and maximum effect is usually
seen after four to 6 weeks, when the muscle becomes more
flexible. The effect is reversible. Improving gait in children
who can walk but in whom spasticity is an obstacle is one
indication.
The muscle is theoretically weakened by blocking nerve
impulses to the muscle fibers, and muscle weakness has been
reported in experiments with rabbits and cats (Yaraskavitch et al.,
2008; Fortuna et al., 2011). In studies of BoNT-A treatment
in children with CP, muscle weakness also has been reported,
although only often as comments (Naumann et al., 2006;
O’Flaherty et al., 2011). Before the start of the present study we
found only one study that actually measured muscle strength
(Bjornson et al., 2007). Bjornson et al. compared BoNT-A to a
control group receiving saline injections and found that muscle
strength had increased 24 weeks after treatment in the BoNT-
A group but not in the group receiving saline injections. Thus
the reports are conflicting and it is not fully known how BoNT-A
affects voluntary muscle strength.
Muscle weakness is common in children with CP and has
been described as being more pronounced distally and with
an imbalance across joints (Wiley and Damiano, 1998; Ross
and Engsberg, 2002). It has been shown to correlate with
walking ability, where more than 50% of the predicted normal
strength was associated with the ability to walk without aids
(Eek and Beckung, 2008). A relationship between muscle strength
and gait has been demonstrated in terms of velocity, stride
length, gait kinematics, and the gross motor function measure
(GMFM; Damiano et al., 2000; Desloovere et al., 2006; Ross and
Engsberg, 2007). Gage described five prerequisites for a normal
gait pattern (Gage, 2004); stability in stance, foot clearance in
swing, pre-positioning of the foot for initial contact, adequate
step length, and energy conservation, all of which may be
compromised by muscle weakness. The plantar flexor muscles
are of special interest as they are the major force generators
for forward progression (Kepple et al., 1997; Sadeghi et al.,
2001).
Weakness often co-exists with spasticity. This is almost always
the case in the gastrocnemius muscle in children with CP.
However, muscle strength and selective motor control have
a higher correlation with gait parameters than spasticity and
joint mobility (Ross and Engsberg, 2002; Ostensjo et al., 2004;
Desloovere et al., 2006). With this in mind, it is important not
to make weak muscles even weaker with treatment, with a risk of
compromising gait pattern and walking ability.
The plantar flexor muscle group is difficult to measure in
typically developing children above the age of nine because of
the short lever arm, leading to high forces and difficulties in
stabilizing with a hand held device (Eek et al., 2006). However,
as children with CP often exhibit weakness in the plantar flexors,
this makes it possible to measure muscle strength among children
over 9 years of age as well.
The primary aim of the study was to describe the effect on
muscle strength in the lower extremities after BoNT-A injections
in children with CP by means of measurement of torque.
A secondary aim was to relate the effect of BoNT-A to gait pattern
and joint range of motion.
MATERIALS AND METHODS
Participants
Children with spastic CP were recruited consecutively from
the spasticity clinic at the Regional Rehabilitation Centre in
Gothenburg, Sweden. Inclusion criteria were increased muscle
tone interfering with motor function/gait pattern and ability
to walk without support. Twenty-three children were recruited;
three were lost to follow-up (due to not returning for follow-
up), resulting in a total of 20 children, 8 girls and 12
boys with a mean age of 7 years 8 months at injection
(SD 2:9). Sixteen children had unilateral spastic CP and four
bilateral spastic CP, according to the CP classification by
Surveillance of Cerebral Palsy in Europe (SCPE, 2000). Nineteen
children were classified at level I, according to the gross
motor function classification system (GMFCS) and one with
bilateral spastic CP at level II (Palisano et al., 2006). Their
mean weight was 27.3 kg (SD 11.7) and mean height 125.5
(SD 17.4).
Procedure
The children were tested three times: at baseline before treatment
with BoNT-A, at peak effect around 6 weeks after, and at a follow-
up when the effect leveled off around 24 weeks after injection.
BoNT-A injections (Botox R©; Allergan or Dysport R©, Ipsen)
were made during sedation with ketamine and midazolam
in combination (rectal administration), or with nitrous oxide
sedation, after local anesthetic EMLA R© cream was applied
to injection sites. Injections were guided with neuromuscular
electric stimulation; using Teflon-coated Botox needles (37 mm,
27 gage) diluted to100 Units (U)/mL. Doses were calculated
according to size of the muscle, body weight, and degree of
spasticity (Love et al., 2010).
Measurements of muscle strength were made in four muscle
groups (knee: extensors and flexors, ankle: dorsi- and plantar
flexors) with a handheld device (Chatillon, AMETEK Test &
Calibration Instruments, USA) using the “make” technique
and standardized positions. The positions used in this study
were similar to a normative study (Eek et al., 2006). Three
attempts were made after instruction and familiarization with
the procedure, and the maximum recording was used for
data analysis. The lever arm for each muscle group was
measured with a tape measure, and torque was calculated
and normalized to body weight (Nm/kg). Muscle strength in
children with CP can be measured with good reliability with a
handheld electronic myometer (Berry et al., 2004; Taylor et al.,
2004).
A two-dimensional gait analysis was performed in all legs
with BoNT-A injections in the gastrocnemius muscle, with
registration of spatiotemporal data and joint kinematics. For
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data acquisition, we used a motion capture camera with a
sampling rate of 50 Hz (Oqus, Qualisys AB, Göteborg, Sweden),
placed at a distance of 3 m from the subject. Four markers
(∅ 16 mm) were attached with double-sided adhesive tape to
the skin at bony landmarks (trochanter major, lateral knee
joint, lateral malleolus, and head of metatarsale V). Data was
processed with the QTM software (Qualisys AB, Göteborg,
Sweden) and exported to an excel worksheet for calculation of
gait velocity, stride length, and joint angles in the knee and
ankle, using the coordinates of the reflective markers. The same
examiner, who has 15 years of experience with the method,
placed the markers. Children walked barefoot, and measurements
where parents confirmed that the gait pattern was relaxed
and typical for the child were chosen for analysis. Values for
joint angles at initial contact, as well as peak values for knee
extension and dorsiflexion in stance were used for statistical
testing.
Passive range of motion (ROM) was measured with a plastic
goniometer. Spasticity was graded according to a modified
Ashworth scale (Bohannon and Smith, 1987) with the children
lying supine in a relaxed position with head in midline.
The children received physiotherapy during 2–3 months post
injection with their regular therapist, with individual programs
focusing on active movements and selective control around the
ankle, as well as activities including gait and balance.
One month after injection, parents were interviewed or asked
to fill in a questionnaire about the effect of the treatment. This
was reported as a positive and/or negative effect and graded as:
no effect, small effect, moderate effect or large effect.
This study was approved by the Regional Ethics Review Board,
University of Gothenburg, with written informed consent from
parents of all subjects.
Statistical Analysis
According to a previous study on muscle strength training in
children with CP, a sample size of 17 was sufficient to analyze
change in muscle strength with a power of 0.8 (Eek et al., 2008).
Muscle strength in the plantar flexor group was analyzed
in children given injections in the gastrocnemius muscles, and
knee flexor strength was analyzed for injections in the hamstring
muscles. Muscle strength in the corresponding muscle groups
in untreated legs served as controls. Muscle strength in the
antagonists (ankle dorsiflexors and knee extensors) was also used
for comparison.
Data were tested for normality with the Shapiro–Wilks test.
It was found that all variables were not normally distributed,
and non-parametric methods were thus used for analysis. Data
were analyzed with the Mann–Whitney U-test for comparison
between treated and control legs at baseline. Repeated measures
ANOVA was used for comparison before and after treatment,
and with a post hoc test with Bonferroni correction for multiple
comparisons, for variables showing a statistically significant
difference in the ANOVA test. When assumption of sphericity
was violated, the Greenhouse–Geisser correction was used.
The software packages Statview and SPSS were used for the
analyses. A p-value less than 0.05 was considered statistically
significant.
RESULTS
Both legs were treated in children with bilateral involvement; in
total the gastrocnemius muscles of 24 legs/20 children received
injections with BoNT-A. In addition the soleus muscles were
treated in 9 legs/9 children and m. tibialis posterior in 10 legs/8
children. Eight legs/six children had injections in hamstring
muscles. Mean dose/kg bodyweight injected into gastrocnemius
was (Botox R©) 3.2 Allergan units/kg, or (Dysport R©) 6 units/kg;
mean dose in hamstrings (Botox R©) 1.5 Allergan units/kg, or
(Dysport R©) 2.5 units/kg.
Three children wore lower limb casts after the injection; one
child wore a cast for 2 weeks and two children for 2+2 weeks. The
casts were put on 2 weeks after treatment to allow time for muscle
relaxation before the children were given the casts. Measurements
of muscle strength for these children were made at least 2 weeks
after the casts were removed.
Tests at peak effect were made at a mean of 5 weeks and
5 days (SD 1 week 3 days) after injection and were followed up
at 5 months and 3 weeks (SD 1 month) after.
Muscle Strength
Data on muscle strength are presented in Table 1 and Figures 1
and 2. At baseline, plantar flexor muscles subjected to BoNT-
A were weaker than control muscles (p = 0.005, confidence
interval (CI) 0.10; 0.44). There was no difference in plantar flexor
strength at peak toxin effect as compared to baseline. At follow-
up 6 months after treatment, repeated measures ANOVA showed
no difference in control muscles, but a difference in plantar flexor
muscles with BoNT-A injection [F(2,46) = 4.44, p = 0.017],
showing a trend to increased plantar flexor strength (CI −0.25;
−0.01). The opposite pattern was found in the knee flexor group,
with no change in knee flexors treated with BoNT-A but an
increase in control muscles [F(1.7,52.3) = 4.60, p = 0.019] (CI
−0.14; −0.02). In the antagonistic muscle groups, there was no
change of strength in dorsiflexors, but increased muscle strength
in knee extensors [F(2,78)= 8.38, p= 0.001] (CI−0.31;−0.07).
Gait
There was no difference in gait velocity or stride length after
treatment.
Kinematic gait data from all three occasions were available in
23 legs/20 children with BoNT-A treatment in the gastrocnemius.
At peak effect, the 2D gait analysis showed a small improvement
in knee extension at initial contact [F(2,44) = 3.78, p = 0.031]
(CI 1.1; 6.5). At baseline the ankle was in plantar flexion at initial
contact in all but two legs subject to BoNT-A treatment. There
were no differences regarding ankle angle in gait after treatment.
Muscle Tone and Passive ROM
Spasticity grading of the gastrocnemius muscle at baseline was
available in 35 legs (23 with BoNT-A and 12 controls). Muscle
tone at baseline was increased in legs planned for treatment
(grade 1 in 13, grade 1+ in 6, and grade 2 in 4) and in five control
legs (grade 1). Grading of spasticity after treatment was available
in 14 of the legs treated with BoNT-A. There was a decrease in
muscle tone in 7 legs and no change in the rest.
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TABLE 1 | Muscle strength, gait data and range of motion at baseline, peak effect and follow-up, presented as median (interquartile range).
Baseline Peak effect Follow up ANOVA diff 1-2 diff 1-3
Muscle strength Nm/kg n p
Plantar flexors BoNT-A 24 0.94 (0.38)† 0.88 (0.38) 1.02 (0.43) 0.017 1.000 0.069
control 14 1.20 (0.25)† 1.25 (0.25) 1.20 (0.39) 0.660
Knee flexors BoNT-A 8 0.91 (0.33) 0.89 (0.43) 0.89 (0.35) 0.445
control 32 0.90 (0.29) 1.04 (0.29) 1.00 (0.34) 0.019 0.036 0.008
Dorsiflexors 40 0.31 (0.15) 0.32 (0.17) 0.34 (0.20) 0.916
Knee extensors 40 1.37 (0.52) 1.52 (0.69) 1.48 (0.75) 0.001 0.180 0.001
Gait data for legs with gastrocnemius injections
Velocity m/sec 20 1.06 (0.18) 1.06 (0.18) 1.11 (0.19) 0.159
Stride length 20 0.98 (0.24) 0.98 (0.18) 1.04 (0.27) 0.060
Knee angle at initial contact (◦) 22 19.8 (14.9) 17.7 (9.6) 20.7 (14.4) 0.031 0.035 0.469
Knee extension in stance (◦) 23 11.8 (11.8) 11.4 (9.9) 10.2 (9.6) 0.100
Ankle angle at initial contact (◦) 23 −7.0 (13.9) −7.9 12.4) −8.3 (9.9) 0.414
Dorsiflexion in stance (◦) 23 8.2 (7.4) 9.5 (8.5) 6.6 (4.4) 0.619
Range of motion
Passive dorsiflexion with extended knee (◦) 15 15.0 (8.8) 15.0 (9.5) 18.0 (11.0) 0.048 0.058 0.114
p-values (in italic) for ANOVA and at peak effect and follow up compared to measurement at baseline for variables with a statistically significant ANOVA test. Statistically
significant differences indicated in bold figures. †Statistically significant difference between muscles treated with botulinum neurotoxin-A (BoNT-A) and control muscles at
baseline p = 0.004.
Data on passive dorsiflexion in the ankle at baseline were
available in 31 legs (19 BoNT-A and 12 controls). There was a
statistically significant difference (p< 0.001, CI 7.8; 18.1) between
muscles planned for injection (median 15.0◦, interquartile range
(IQR) 8.8) compared to controls (median 22.5◦, IQR 11.0). Data
from all three occasions were available in 15 legs treated with
BoNT-A in the gastrocnemius (Table 1). There was a small
increase in passive dorsiflexion [F(2,28)= 3.40, p= 0.048].
Parent Reports
The parent reports all indicated positive effects graded as: small
(three children), moderate (eight children), and large (nine
children). Some parents specifically mentioned that their child
was not walking on toe and could more easily make heel contact.
One child had pain for a couple of weeks after the casts, and one
child felt insecure/weak in the first weeks after injection.
DISCUSSION
The primary aim of the study was to see whether voluntary
muscle strength is affected by BoNT-A, with a focus on plantar
flexor muscles, as being important for walking. We found no
sign of decreased torque in plantar flexor muscles at the point
at which the toxin effect was at its peak. There was instead an
increasing trend in strength at follow-up in muscles treated with
BoNT-A. No increase was seen in the untreated plantar flexors
that acted as controls during the study period. This finding is
similar to that in a study by Bjornson et al. (2007) who found
increased muscle strength 6 months after treatment compared
to saline injections. Williams et al. (2013b) found no difference
in strength 5 weeks after injections in the gastrocnemius, while
Barber et al. (2013) found an increased muscle volume after
FIGURE 1 | Muscle strength in plantar flexor muscles at baseline, peak
effect and follow-up after botulinum neurotoxin-A (BoNT-A) treatment.
Data in torque normalized to body weight (Nm/kg), presented as mean and
with SD error bars.
BoNT-A treatment, suggesting increased muscle strength. In
reports of adverse effects, weakness is mentioned as occurring
over short transient periods during the first weeks after injection
(Naumann et al., 2006; O’Flaherty et al., 2011). The parents of one
child in our study reported a transient period of muscle weakness
in the first days/first week after injection.
It has been demonstrated that the concurrent treatment of
BoNT-A and strength training can achieve positive outcomes in
terms of strength, spasticity and for the achievement of functional
goals (Williams et al., 2013a). Physiotherapy after injection in our
study focused on voluntary control in the ankle, and exercises
in standing balance and gait. Many of these activities, as well
as everyday life, include using both legs, and both legs thus
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FIGURE 2 | Muscle strength in plantar flexor muscles at baseline, peak effect and follow-up after BoNT-A treatment. Data in torque normalized to body
weight (Nm/kg), presented as boxes indicating 25–75 percentile, a line indicating median and circles showing observations outside 10 or 90 percentile.
receiving about the same amount of muscle activity. In our study,
most of the children had injections in only one leg, and in
this way muscle strength development in not injected muscles
in the other leg could serve as control to injected muscles.
Spasticity, muscle weakness, and poor voluntary control often
co-exist in children with CP (Gormley, 2001). The increasing
trend in muscle strength in plantar flexors after BoNT-A can
be explained as an effect of the blocking of involuntary nerve
impulses leading to an opportunity to take better voluntary
control, and the increasing trend in muscle strength as an effect
of training and using the muscle with voluntary control. As
standing and gait involves muscle activity in the whole leg it
may not be surprising that there was also increased muscle
strength in knee extensors and knee flexors. Contrary to this
we found no change in ankle dorsiflexors. In growing children,
6 months may be sufficient time for a natural increase in
muscle strength and here the not injected muscles also can
serve as controls. According to a previous study of muscle
strength in children with CP, 5-15 years of age (Eek, 2009),
there is an increase in torque with age for knee extensors and
knee flexors, but not for ankle plantar and dorsiflexors. The
findings in the present study can therefore be interpreted as an
expected development for knee extensors, knee flexors and ankle
dorsiflexors.
Gait pattern improved regarding knee extension at initial
contact in legs with BoNT-A treatment in the gastrocnemius,
but there were no changes in ankle angle in the gait analysis.
This is different from previously reported findings of improved
peak ankle dorsiflexion in stance after BoNT-A (Sutherland
et al., 1999). Interestingly, parents reported improvement in
heel strike and foot contact, which is similar to a study with
video analysis, who found improvement in initial foot contact
following BoNT-A (Ubhi et al., 2000). However, an improved
position in the knee at initial contact and during the stance
phase facilitates the possibility to make heel contact (which is
easy to see with the eye) while the exact angle in the knee
and ankle is difficult to see without instrumented measurement.
In contrast to the lack of improved dorsiflexion in gait, there
was increased passive ROM in the ankle which was small but
statistically significant. Even small differences can be clinically
relevant if the increase in dorsiflexion is close to the neutral
position of the ankle, and letting the ankle dorsiflex a few
degrees can be what is needed for a better gait pattern. The
lack of change in ankle angle in the gait pattern may be
explained by weakness in dorsiflexors, and also the fact that
as a bi-articular muscle the improved range of motion in
gastrocnemius was gained at the proximal end, thus facilitating
knee extension.
The children in the study did not have very severe spasticity,
most of them with a grade 1–1+ according to the Ashworth scale,
with a resistance to quick stretch at the end or in the second half of
the movement. There was decreased spasticity in only half of the
treated legs after treatment. This may depend on the Ashworth
scale as a subjective way of testing and also that muscle tone
may vary with the situation, and if the child is excited. Testing
was, however, performed in a standardized way with the child in
rest, lying supine with the head in midline. This position does
not always reflect what is happening in activity and at baseline
assessment it was visible that there was an increase in muscle tone
in activity, affecting movement patterns. There is yet no way (that
we know of) of measuring muscle tone in activity in a clinical
setting.
Limitations
There are some limitations that need to be acknowledged in
this study. There was a variety in location of injections; some
children were also given injections in soleus, tibialis posterior,
and hamstring muscles in addition to gastrocnemius. This makes
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the sample heterogeneous but they were considered too few to
be possible to analyze as subgroups in this study. Three children
were immobilized in the ankle by casts for 2 weeks after BoNT-A,
to increase stretch. This immobilization can induce weakness and
for that reason measurement of muscle strength was performed
at least 2 weeks after removal of the casts, to let them regain some
muscle strength.
However, the primary aim and focus of the study was to
measure whether muscle strength deteriorated, and we found that
this was not the case. There was instead an increasing trend in
muscle strength at follow-up.
Clinical Implications
Voluntary force production in plantar flexor muscles was not
decreased by BoNT-A. Muscle strength instead showed an
increasing trend at follow-up. Gait pattern improved in terms of
better knee extension in stance.
Adequate muscle strength is important for maintaining the
ability to walk. Knowledge of how a treatment affects muscle
strength is necessary when selecting interventions in order not
to make muscles weaker with treatment.
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